Increased natural killer cells and decreased CD3(+)CD8(+)CD62L(+) T cells in CML patients who sustained complete molecular remission after discontinuation of imatinib

Br J Haematol. 2012 Apr;157(2):254-6. doi: 10.1111/j.1365-2141.2011.08939.x. Epub 2011 Nov 11.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / administration & dosage*
  • Benzamides
  • CD3 Complex / blood
  • CD3 Complex / immunology*
  • CD8 Antigens / blood
  • CD8 Antigens / immunology*
  • CD8-Positive T-Lymphocytes / immunology*
  • CD8-Positive T-Lymphocytes / metabolism
  • Female
  • Humans
  • Imatinib Mesylate
  • Killer Cells, Natural / immunology*
  • Killer Cells, Natural / metabolism
  • L-Selectin / blood
  • L-Selectin / immunology*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / blood
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / immunology*
  • Lymphocyte Count
  • Male
  • Piperazines / administration & dosage*
  • Pyrimidines / administration & dosage*
  • Remission Induction

Substances

  • Antineoplastic Agents
  • Benzamides
  • CD3 Complex
  • CD8 Antigens
  • Piperazines
  • Pyrimidines
  • L-Selectin
  • Imatinib Mesylate